I recently had the opportunity to sit down with Danny Levine for an episode of his RARECast podcast to discuss something I’m deeply passionate about: how real-world data (RWD) is transforming the landscape of rare disease research. As someone who has spent my...
At the recent SCOPE Europe conference, I spoke about a fundamental shift redefining the future of clinical research. Access to real-world data (RWD) is no longer the challenge; our ability to interact with it is. The barrier lies in the friction between researchers...
When we think about the future of clinical research, it’s easy to picture gleaming technology, seamless data flows, and a world where trials are faster, smarter, and more inclusive. But let’s be honest. We’re not there yet. That’s exactly the conversation I had in...
The clinical trial industry faces a persistent and costly challenge: poor site selection. With up to 85% of trials failing to meet enrollment targets due in part to suboptimal site identification, the path from promising therapeutic concept to patient access remains...
In today’s era of exponential data growth, real-world data (RWD) is abundant, but its value hinges on our ability to interpret it with speed, scale, and precision. That’s where artificial intelligence (AI) comes into play. At TriNetX, we’re seeing firsthand how the...
As I sat down with Dr. Monique Adams of Sanofi for our most recent episode of The Future Prescription: Inside the Trends vodcast, I was reminded just how critical it is to move conversations about representativeness in clinical trials from aspiration to action....
